vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and SR Bancorp, Inc. (SRBK). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $8.4M, roughly 1.1× SR Bancorp, Inc.). SR Bancorp, Inc. runs the higher net margin — 10.0% vs -60.3%, a 70.3% gap on every dollar of revenue. On growth, SR Bancorp, Inc. posted the faster year-over-year revenue change (6.4% vs -49.9%). SR Bancorp, Inc. produced more free cash flow last quarter ($3.1M vs $1.6M). Over the past eight quarters, SR Bancorp, Inc.'s revenue compounded faster (-2.4% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
SR Bancorp Inc. is a regional bank holding company based in the United States. It offers a full range of consumer and commercial banking services including deposit products, personal loans, mortgage lending, small business financing, and commercial credit solutions, primarily serving local communities and small to mid-sized enterprises in its operating areas.
PLX vs SRBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $8.4M |
| Net Profit | $-5.5M | $834.0K |
| Gross Margin | 49.4% | — |
| Operating Margin | -51.1% | 13.0% |
| Net Margin | -60.3% | 10.0% |
| Revenue YoY | -49.9% | 6.4% |
| Net Profit YoY | -184.8% | -18.3% |
| EPS (diluted) | $-0.06 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $8.4M | ||
| Q3 25 | $17.9M | $8.2M | ||
| Q2 25 | $15.7M | $7.6M | ||
| Q1 25 | $10.1M | $7.7M | ||
| Q4 24 | $18.2M | $7.9M | ||
| Q3 24 | $18.0M | $8.4M | ||
| Q2 24 | $13.5M | $7.9M | ||
| Q1 24 | — | $8.8M |
| Q4 25 | $-5.5M | $834.0K | ||
| Q3 25 | $2.4M | $693.0K | ||
| Q2 25 | $164.0K | $2.2M | ||
| Q1 25 | $-3.6M | $537.0K | ||
| Q4 24 | $6.5M | $1.0M | ||
| Q3 24 | $3.2M | $1.4M | ||
| Q2 24 | $-2.2M | $-3.0M | ||
| Q1 24 | — | $1.1M |
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -51.1% | 13.0% | ||
| Q3 25 | 11.9% | 11.0% | ||
| Q2 25 | 7.5% | 32.1% | ||
| Q1 25 | -41.0% | 8.1% | ||
| Q4 24 | 39.6% | 17.1% | ||
| Q3 24 | 22.2% | 20.6% | ||
| Q2 24 | -18.0% | -34.0% | ||
| Q1 24 | — | 15.4% |
| Q4 25 | -60.3% | 10.0% | ||
| Q3 25 | 13.2% | 8.5% | ||
| Q2 25 | 1.0% | 29.2% | ||
| Q1 25 | -35.8% | 7.0% | ||
| Q4 24 | 35.6% | 13.0% | ||
| Q3 24 | 18.0% | 16.3% | ||
| Q2 24 | -16.4% | -38.2% | ||
| Q1 24 | — | 12.1% |
| Q4 25 | $-0.06 | $0.11 | ||
| Q3 25 | $0.03 | $0.09 | ||
| Q2 25 | $0.00 | $0.27 | ||
| Q1 25 | $-0.05 | $0.06 | ||
| Q4 24 | $0.10 | $0.12 | ||
| Q3 24 | $0.03 | $0.16 | ||
| Q2 24 | $-0.03 | $8.14 | ||
| Q1 24 | — | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $81.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $188.5M |
| Total Assets | $82.3M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $81.8M | ||
| Q3 25 | $13.6M | $58.3M | ||
| Q2 25 | $17.9M | $57.8M | ||
| Q1 25 | $19.5M | $62.2M | ||
| Q4 24 | $19.8M | $53.4M | ||
| Q3 24 | $27.4M | $47.3M | ||
| Q2 24 | $23.4M | $45.9M | ||
| Q1 24 | — | $72.5M |
| Q4 25 | $48.2M | $188.5M | ||
| Q3 25 | $52.9M | $191.9M | ||
| Q2 25 | $49.9M | $193.8M | ||
| Q1 25 | $45.2M | $195.1M | ||
| Q4 24 | $43.2M | $198.1M | ||
| Q3 24 | $32.4M | $200.5M | ||
| Q2 24 | $28.6M | $199.5M | ||
| Q1 24 | — | $199.3M |
| Q4 25 | $82.3M | $1.1B | ||
| Q3 25 | $82.3M | $1.1B | ||
| Q2 25 | $78.5M | $1.1B | ||
| Q1 25 | $73.9M | $1.1B | ||
| Q4 24 | $73.4M | $1.1B | ||
| Q3 24 | $61.6M | $1.1B | ||
| Q2 24 | $91.5M | $1.0B | ||
| Q1 24 | — | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $3.6M |
| Free Cash FlowOCF − Capex | $1.6M | $3.1M |
| FCF MarginFCF / Revenue | 17.8% | 37.0% |
| Capex IntensityCapex / Revenue | 4.4% | 5.9% |
| Cash ConversionOCF / Net Profit | — | 4.31× |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $11.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $3.6M | ||
| Q3 25 | $-3.7M | $1.2M | ||
| Q2 25 | $-5.2M | $4.7M | ||
| Q1 25 | $-5.1M | $2.6M | ||
| Q4 24 | $4.0M | $-1.4M | ||
| Q3 24 | $4.1M | $1.8M | ||
| Q2 24 | $-3.6M | $-1.7M | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | $1.6M | $3.1M | ||
| Q3 25 | $-4.2M | $1.1M | ||
| Q2 25 | $-5.7M | $4.2M | ||
| Q1 25 | $-5.4M | $2.5M | ||
| Q4 24 | $3.6M | $-1.5M | ||
| Q3 24 | $4.0M | $1.7M | ||
| Q2 24 | $-3.8M | $-2.8M | ||
| Q1 24 | — | $-4.0M |
| Q4 25 | 17.8% | 37.0% | ||
| Q3 25 | -23.7% | 14.0% | ||
| Q2 25 | -36.2% | 55.9% | ||
| Q1 25 | -53.0% | 32.3% | ||
| Q4 24 | 19.6% | -19.5% | ||
| Q3 24 | 22.4% | 20.3% | ||
| Q2 24 | -28.1% | -35.8% | ||
| Q1 24 | — | -45.2% |
| Q4 25 | 4.4% | 5.9% | ||
| Q3 25 | 2.8% | 0.9% | ||
| Q2 25 | 2.8% | 5.7% | ||
| Q1 25 | 3.0% | 1.0% | ||
| Q4 24 | 2.3% | 1.3% | ||
| Q3 24 | 0.5% | 1.0% | ||
| Q2 24 | 1.3% | 13.9% | ||
| Q1 24 | — | 0.5% |
| Q4 25 | — | 4.31× | ||
| Q3 25 | -1.58× | 1.76× | ||
| Q2 25 | -31.91× | 2.11× | ||
| Q1 25 | — | 4.79× | ||
| Q4 24 | 0.61× | -1.40× | ||
| Q3 24 | 1.27× | 1.31× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -3.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
SRBK
Segment breakdown not available.
